Delayed Start to Ovarian Stimulation

• Status: Terminated
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

In couples with infertility secondary to Diminished Ovarian Reserve, the investigators hypothesize that a delayed start (7 day) to ovarian stimulation with an GnRH antagonist (Ganirelix) will improve oocyte maturation and quality, and improve pregnancy outcomes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Ganirelix

Criteria

Inclusion Criteria:

• Antral Follicle Count (AFC) less than or equal to 4 as measured by transvaginal ultrasound (TVUS), or

• Cancellation of a prior IVF cycle due to poor ovarian response.

• Patients will receive an antagonist stimulation protocol for IVF, or IVF with Intracytoplasmic Sperm Injection (ICSI).

Exclusion Criteria:

• Severe male factor infertility requiring surgical intervention to obtain sperm

• Major uterine abnormality,

• Preimplantation genetic diagnostic (PGD) testing,

• Planned cycles without embryo transfer (for example, freeze-all, donor, or surrogate cycles).